Oxford Immunotec Global, which sells diagnostic tests for latent tuberculosis infection (LTBI), raised $64 million by offering 5.4 million shares (all primary) at $12, below the range of $13 to $15. Oxford, which initially filed confidentially on 9/10/2013, plans to list on the NASDAQ under the symbol "OXFD". J.P. Morgan and Piper Jaffray acted as the lead managers on the deal.
